BPMC News and Press, Blueprint Medicines Corporation From 03/24/20

Blueprint Medicines ( BPMC ) announced that it had achieved positive results from a phase 2 study using its cancer drug avapritinib treating patients with indolent systemic mastocytosis (SM). Not only did this drug achieve the clinical endpoints, but it is able to move on to part 2 of th...

Today, we will see why Blueprint Medicines Corporation ( BPMC ) is an attractive pick in 2020. Company overview Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines Corporation went public in 2015. The company is developing precision therapies by leveraging ...

Business disruptions due to COVID-19 represent a new risk for investors across all sectors. Expect to see language addressing this added to the risk factors section of 10-K annual reports filed with the Securities and Exchange Commission (SEC). For biotech and pharma companies, COVID-19 will im...

Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Neutral rating and $45 (107% upside) price target at Goldman Sachs. More news on: Arrowhead Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, , Read more...

The following slide deck was published by Blueprint Medicines Corporation in conjunction with this Read more ...

Updated results from Part 1 of a Phase 2 clinical trial, PIONEER , evaluating Blueprint Medicines' ( BPMC +4.9% ) lead drug avapritinib (BLU-285) in patients with indolent systemic mastocytosis (SM) showed encouraging action. More news on: Blueprint Medicines Corporation, Health...

CAMBRIDGE, Mass. , March 16, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated results from the Phase 2 PIONEER trial of avapritinib ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

CAMBRIDGE, Mass. , March 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reaffirmed previously announced plans to host a live conference call...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen&#...